FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

Ilaria Mancini; Carla Valsecchi; Luca Andrea Lotta; Louis Deforche; Silvia Pontiggia; Mariateresa Bajetta; Roberta Palla; Karen Vanhoorelbeke; Flora Peyvandi

doi:10.1160/TH13-08-0688

FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

Ilaria Mancini, Carla Valsecchi, Luca Andrea Lotta, Louis Deforche, Silvia Pontiggia, Mariateresa Bajetta, Roberta Palla, Karen Vanhoorelbeke, Flora Peyvandi

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Collagen-binding activity (CBA) and FRETS-VWF73 assays are widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von Willebrand factor (VWF) cleaving-protease. Accurately assessing the severe deficiency of ADAMTS13 is important in the management of thrombotic thrombocytopenic purpura (TTP). However, non-concordant results between the two assays have been reported in a small but relevant percentage of TTP cases. We investigated whether CBA or FRETS-VWF73 assay reflects ADAMTS13 proteolytic activity in acquired TTP patients with non-concordant measurements. Twenty plasma samples with non-concordant ADAMTS13 activity results,

Original language	English
Pages (from-to)	297-303
Number of pages	7
Journal	Thrombosis and Haemostasis
Volume	112
Issue number	2
DOIs	https://doi.org/10.1160/TH13-08-0688
Publication status	Published - 2014

Keywords

ADAMTS13 activity assay
Autoantibodies
Flow assay
TTP
Von Willebrand factor

ASJC Scopus subject areas

Hematology
Medicine(all)

Access to Document

10.1160/TH13-08-0688

Cite this

@article{52a5d2a056e547698d03ffd1a9a825a9,

title = "FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients",

abstract = "Collagen-binding activity (CBA) and FRETS-VWF73 assays are widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von Willebrand factor (VWF) cleaving-protease. Accurately assessing the severe deficiency of ADAMTS13 is important in the management of thrombotic thrombocytopenic purpura (TTP). However, non-concordant results between the two assays have been reported in a small but relevant percentage of TTP cases. We investigated whether CBA or FRETS-VWF73 assay reflects ADAMTS13 proteolytic activity in acquired TTP patients with non-concordant measurements. Twenty plasma samples with non-concordant ADAMTS13 activity results, ",

keywords = "ADAMTS13 activity assay, Autoantibodies, Flow assay, TTP, Von Willebrand factor",

author = "Ilaria Mancini and Carla Valsecchi and Lotta, {Luca Andrea} and Louis Deforche and Silvia Pontiggia and Mariateresa Bajetta and Roberta Palla and Karen Vanhoorelbeke and Flora Peyvandi",

year = "2014",

doi = "10.1160/TH13-08-0688",

language = "English",

volume = "112",

pages = "297--303",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "2",

}

TY - JOUR

T1 - FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

AU - Mancini, Ilaria

AU - Valsecchi, Carla

AU - Lotta, Luca Andrea

AU - Deforche, Louis

AU - Pontiggia, Silvia

AU - Bajetta, Mariateresa

AU - Palla, Roberta

AU - Vanhoorelbeke, Karen

AU - Peyvandi, Flora

PY - 2014

Y1 - 2014

N2 - Collagen-binding activity (CBA) and FRETS-VWF73 assays are widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von Willebrand factor (VWF) cleaving-protease. Accurately assessing the severe deficiency of ADAMTS13 is important in the management of thrombotic thrombocytopenic purpura (TTP). However, non-concordant results between the two assays have been reported in a small but relevant percentage of TTP cases. We investigated whether CBA or FRETS-VWF73 assay reflects ADAMTS13 proteolytic activity in acquired TTP patients with non-concordant measurements. Twenty plasma samples with non-concordant ADAMTS13 activity results,

AB - Collagen-binding activity (CBA) and FRETS-VWF73 assays are widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von Willebrand factor (VWF) cleaving-protease. Accurately assessing the severe deficiency of ADAMTS13 is important in the management of thrombotic thrombocytopenic purpura (TTP). However, non-concordant results between the two assays have been reported in a small but relevant percentage of TTP cases. We investigated whether CBA or FRETS-VWF73 assay reflects ADAMTS13 proteolytic activity in acquired TTP patients with non-concordant measurements. Twenty plasma samples with non-concordant ADAMTS13 activity results,

KW - ADAMTS13 activity assay

KW - Autoantibodies

KW - Flow assay

KW - TTP

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=84905176550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905176550&partnerID=8YFLogxK

U2 - 10.1160/TH13-08-0688

DO - 10.1160/TH13-08-0688

M3 - Article

C2 - 24740645

AN - SCOPUS:84905176550

VL - 112

SP - 297

EP - 303

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -

FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this